To determine whether WR 2721 causes hypocalcemia by enhancing the exit of calcium from the circulation or inhibiting its entry, the drug was infused 3 h after administration of 45Ca to rats. WR 2721 did not significantly increase the rate of disappearance of 45Ca from the circulation even though serum calcium fell by 19%. However, serum 45Ca specific activity was higher at 1.5 h (P < 0.01) and 3 h (P < 0.05) in rats given WR 2721 than in rats given vehicle alone, which suggests that WR 2721 blocks the entry of nonradioactive calcium into the circulation, presumably from bone.
in eight chronically parathyroidectomized rats on a low phosphate diet, WR 2721 reduced serum calcium from 9.4±0.6 to 7.7±0.5 mg/dl (P < 0.01) at 3 h. Furthermore, in dogs rendered hypercalcemic by continuous infusion of PTH, WR 2721 reduced serum calcium from 11.0±0.5 to 10.6±0.5 mg/dl (P < 0.01).
To determine whether WR 2721 causes hypocalcemia by enhancing the exit of calcium from the circulation or inhibiting its entry, the drug was infused 3 h after administration of 45Ca to rats. WR 2721 did not significantly increase the rate of disappearance of 45Ca from the circulation even though serum calcium fell by 19%. However, serum 45Ca specific activity was higher at 1.5 h (P < 0.01) and 3 h (P < 0.05) in rats given WR 2721 than in rats given vehicle alone, which suggests that WR 2721 blocks the entry of nonradioactive calcium into the circulation, presumably from bone.
In incubations with fetal rat long bone labeled in utero with 45Ca, 10-3 M WR 2721 inhibited PTH-stimulated, but not base-line release of 45Ca. Bone resorption by primary culture of chick osteoclasts was inhibited by WR 2721 at concentrations as low as 10-4 M in the absence of hormonal stimulation. These studies suggest that WR 2721 lowers serum calcium predominantly by blocking calcium release from bone. This acute hypocalcemic effect is at least in part independent of its effect on the parathyroid glands, and is most likely a direct effect of the agent on bone resorption.
We recently reported that S-2(3-aminopropylamino)ethylphosphorothioic acid' (WR 2721)2 produces acute transient hypocalcemia in humans (1) . WR 2721 is an organic thiophosphate and sulfhydryl donor that protects cells against the lethal effects of ionizing radiation and alkylating agent chemotherapy (2) . In the murine model, it protects skin and bone marrow from radiation but does not increase the radiation resistance of mammary tumors (3, 4) . During clinical trials to determine the toxicity and effectiveness of this compound as a radio-and chemoprotector in humans receiving antitumor therapy, hypocalcemia was serendipitously discovered. In normocalcemic patients given a single intravenous infusion of WR 2721 (740 mg/M2), serum calcium levels decreased 23% in 2 h and remained depressed for at least 24 h. WR 2721-induced hypocalcemia was also accompanied by a fall in serum immunoreactive parathyroid hormone (PTH) concentration and urinary cyclic AMP excretion (1) . These clinical observations, as well as the in vitro demonstration that WR 2721 blocked the release of PTH from isolated bovine parathyroid cells (1) , suggested that acute inhibition of PTH secretion mediates the hypocalcemia induced by WR 2721. The rapid sequence of events, however, does not support this hypothesis. In contrast to WR 2721 administration, serum calcium levels decrease much less rapidly following surgical removal of the parathyroid glands where there is usually no detectable change in serum calcium levels for at least 2-4 h (5). Thus, although WR 2721 acutely inhibits PTH secretion, the rapidity of the fall in serum calcium levels after WR 2721 suggested that inhibition of PTH secretion was not the sole mechanism.
The present study was undertaken to evaluate further mechanisms by which WR 2721 acutely produces hypocalcemia. Using PTH-infused dogs and parathyroidectomized (PTX) rats, we show that WR 2721 produces hypocalcemia by a mechanism independent of its inhibition of PTH secretion. By analyzing the kinetics of 45Ca in rats we find evidence that WR 2721 lowers serum calcium by inhibiting the flux of calcium into the circulation, apparently by reducing bone resorption. Further, using fetal rat bone organ cultures and primary cultures of avian osteoclasts, we establish that WR 2721 directly inhibits bone resorption. These additional studies suggest that the acute hypocalcemic action of WR 2721 is mediated by a dual mechanism, resulting in the direct and indirect inhibition of osteoclastic bone resorption.
Methods
In vivo experiments Studies in rats. Male Sprague-Dawley rats weighing 120-200 g were fed a standard rat diet containing 1.0% phosphorus and 1.0% calcium or, when specified, a low phosphorus diet containing 0.02% phosphorus and 0.8% calcium (ICN Nutritional Biochemicals, Cleveland, OH). Food, but not water, was withheld for 16 h before each experiment. WR 2721 or vehicle was administered by rapid infusion (<15 s) into a tail vein or intraperitoneally. Blood samples were obtained by cardiac puncture with a 26-gauge needle during light ether anesthesia. WR 2721 was dissolved no more than 15 min before administration in a solution containing 40 mM sodium chloride and 40 mM sodium bicarbonate (final pH 7.5), to give a final concentration of 30 mg/ml.
Parathyroidectomy was performed under sodium pentobarbital anesthesia. Parathyroid glands were visualized under a dissecting microscope and surgically removed, leaving the thyroid glands intact. Sham-operated rats underwent the same procedure including exposure of the parathyroid glands, but the glands were not removed. Rats were considered to have adequate PTX if the serum calcium was <8.0 mg/ dl at 3 and 7 d after PTX when fed the standard rat diet.
In experiments examining the kinetics of acutely injected radiocalcium, 100 gCi/kg body weight of 45CaC12 (New England Nuclear, Boston, MA; 27 Ci/g) was dissolved in normal saline (0.5 ml/kg) and injected into a tail vein 2 h before injection of WR 2721. In experiments examining the kinetics of radiocalcium release from prelabeled bone pools, 45CaCl2 (500 uCi/kg) was injected subcutaneously 17 (5) . PTH was measured by radioimmunoassay using a chicken anti-bovine PTH antisera and 1251 bovine PTH (6) . The assay is predominantly sensitive to C-terminal, mid-region, and intact bovine hormone. The upper limit of normal in dogs is 40 1AI eq/ml.
In vitro experiments
Bone resorption in organ culture. Bone resorption by cells in organ culture was performed using standard techniques (7) . Briefly, the radii and ulnae of day 21 fetal rats, previously radio-labeled in utero by maternal injection of 100 MCi 45CaC12, were dissected free and cultured separately in 0.5 ml BGJ media (Gibco Laboratories, Grand Island, NY) containing 50 sg gentamicin and 1 mg/ml albumin. After a 4-18 h preculture period, bones were transferred to fresh media containing 0 or 10-310-6 M WR 2721, and cultured for S d. Resorption is expressed as percent 45Ca released, and was determined by measuring both 45Ca activity in the culture media and label remaining in the bone rudiment. To some bone-containing wells, 200 or 1,000 ng/ml of (1-34) bovine PTH was added at the beginning of the culture period. Mean values and SEM are calculated from replicates of six for each variable.
Bone resorption by isolated osteoclasts. Osteoclasts were isolated from day 21 hatchling chicks by trypsin digestion of soft tissue marrowfree split segments of tibial bones, using the technique of Osdoby (8) . Histochemical staining and electron microscopy show that 80-90% pure populations of osteoclasts were obtained (8) . As described in preliminary reports, isolated avian osteoclasts can mediate cell contactdependent bone resorption (9) . To determine bone resorptive activity in vitro, one million osteoclasts were suspended with 0.22 mg of 45Ca labeled, devitalized, 75-300-,um diameter bone particles (10) per milliliter of minimum essential medium supplemented with 10% fetal calf serum and 50 ug/ml gentamicin. The cell-bone suspension (0.2 ml) was delivered to the bottom of sterile microtiter wells. The following day, nonadherent cells and bone were removed by aspiration and fresh medium containing 0-I0-' M WR 2721 was added. Cultures were incubated for 1-7 d in humidified 5% CO2 in air at 37°C. Bone resorption is expressed as percent 45Ca release determined by measuring the fraction of radioisotope present in the media and that remaining in the bone (10). Net (cell specific) percent 45Ca release is determined by correcting the total percent 45Ca release for nonspecific release of label due to simple physicochemical exchange.
Morphologic studies. (12, 13) . At the time WR 2721 exerted its maximum hypocalcemic effect (1-2 h), serum levels of phosphorus were unchanged. At 4 h after infusion of WR 2721 there was a slight increase in serum phosphorus (23±6%), however, this was not significantly greater (P < 0.10) than in animals given vehicle alone (9±4%). Moreover, infusion of phosphate as sodium phosphate in amounts equimolar to the quantity in the 30-or 60-mg/kg dose had no effect on the serum calcium (data not shown). These data preclude a rise in extracellular phosphate due to WR 2721 metabolism as a cause of acute hypocalcemia. Though unlikely, we can not exclude the possibility that these effects result from changes in intracellular phosphate levels.
In dogs, WR 2721 produced a similar degree of hypocalcemia. 4 h after infusion of 15 mg/kg WR 2721 in four dogs, there was a significant fall in total serum calcium (10.1±0.14-8.24±0.22 mg/dl, P < 0.001) that was not seen in animals infused with vehicle alone (9.60±0.34-9.16±0.46 mg/dl, P > 0.10). As in our previous finding in humans (1) Effect of WR 2721 infusion on serum calcium in PTX rats.
To determine whether the hypocalcemic effect of WR 2721 occurs independent of the inhibitory effect on the parathyroid gland, we studied its effects in chronically parathyroidectomized rats. Serum calcium 3 d after surgery while on a standard (1%) phosphate diet was 6.0±0.4 mg/dl in PTX rats and 10.2±0.2 mg/100 ml in sham-operated animals (P < 0.0001) (Fig. 2) . PTX and sham-operated rats were then maintained on a low (0.02%) phosphorus diet to raise serum calcium in the PTX rats to the levels observed in the sham-operated animals. After 7 d on a phosphorus-deficient diet, mean serum calcium was 9.6 and 10.2 mg/100 ml in PTX and sham-operated rats (P > 0.05), respectively (Fig. 2) . Thus, at the time of the WR 2721 infusion, the serum calcium levels of the two groups were similar. As shown in Fig. 2 , WR 2721 infusion produced a nearly identical fall in serum calcium in both groups (20.2±2% in PTX and 20.8±1% in sham-operated rats). To confirm that the hypoparathyroid status of the rats had not changed, the rats were once more fed the standard (1.0% phosphorus) diet. Serum calcium concentrations were again lower in all PTX rats (Fig. 2) .
Effects 2721 is independent of its ability to reduce PTH levels. First, WR 2721 infusion into chronically PTX rats produced a fall in serum calcium concentration that was nearly identical to that observed in rats with intact parathyroid glands. Second, WR 2721 lowered the serum calcium concentration when administered to dogs receiving a constant PTH infusion. The hypercalcemic effect of the PTH infusion would have reduced endogenous secretion of PTH; thus, any direct effect of WR 2721 on the parathyroid glands would have little influence on the serum calcium. WR 2721 could produce hypocalcemia by diminishing the entry of calcium into serum from pools such as bone or by enhancing its exit from serum into urine or tissues. Studies of the effect of WR 2721 on the kinetics of 45Ca after acute infusion of the isotope were performed to distinguish between these possibilities. If WR 2721 accelerated the exit of calcium from serum, then total serum calcium and isotopic calcium would be reduced in the same proportion, and the rate of decline of serum 45Ca specific activity would not differ from control animals. We found that when compared with vehicle infused rats, there was only a slightly greater fall in '"Ca activity, whereas serum specific activity was significantly greater in the WR 2721-infused rats at both time points (Fig. 4) . Therefore, the major effect of WR 2721 in lowering calcium appears to be an inhibition of calcium release into serum. (16, 17) , mithramycin (18) , colchicine (19) , and protamine (20), which are believed to cause hypocalcemia by inhibiting bone resorption.
To further characterize the in vivo effects of WR 2721 on radiocalcium kinetics, bone pools of calcium were labeled with 45Ca by injecting the isotope 17 d before WR 2721 administration. WR 2721 lowered both 45Ca activity and total serum calcium in parallel so that there was no change in specific activity (Table I) . These results are consistent with more than one hypocalcemic mechanism; specific activity would not change if WR 2721 enhanced calcium efflux from serum or if it blocked the release of 45Ca into serum from pools (such as bone) that were in isotopic equilibrium with serum. These results are similar to those obtained in two similar studies with calcitonin (17, 21) . Although the results of this particular experiment are inconclusive, the experiment examining radiocalcium kinetics after acute 45Ca infusion suggests that WR 2721 inhibits the entry of calcium into the circulation. The finding that WR 2721 does not enhance urinary calcium excretion in dogs (see below) also lends further support to this hypothesis. These results do not necessarily indicate a direct drug-mediated inhibition of bone cell activity, since decreased bone resorption could have been caused by a reduction in circulating PTH concentration. However, the fact that WR 2721 lowered serum calcium in PTX rats and reduced serum calcium in dogs rendered hypercalcemic by constant PTH infusions suggests a direct effect of WR 2721 on bone resorption.
The results obtained by two different in vitro techniques to assess bone resorption indicate that WR 2721 affects bone cell activity directly. WR 2721, in a dose related fashion, partially inhibited the bone resorptive activity of isolated osteoclasts and blocked the response of osteoclasts in organ culture to PTH. Although results obtained from the in vitro studies complement the in viyo findings, there are important differences. The acute onset (2-3 h) of transient (<24 h in dogs and rats) hypocalcemia produced in vivo contrasts with the slower onset (days) of suppressed 45Ca release in vitro. These differences in the time course may relate to differences in experimental systems. In contrast to in vivo responses, the in vitro bone resorption assays are not sufficiently sensitive to detect significant hour to hour fluctuations in calcium release. Instead, measurable changes in calcium are made possible by integrating the multiple small changes in mineral release that occur over a longer period of observation. The difference in time course may also reflect differences in rates of in vivo drug metabolism. Another difference between the in vitro and in vivo results is that only PTH-stimulated 45Ca release and not base-line release was inhibited by WR 2721 in fetal rudiments, whereas hypocalcemia (presumably due to inhibition of bone resorption) occurred in PTX rats. This can be explained by the conditions of the rudiment bone assay where base-line (unstimulated) resorption is very low, and consequently inhibition of this activity is often not detectable.
No evidence of toxic effects was observed in the cultured cells. By electron microscopy, osteoclasts were free of degenerative changes. There were qualitative changes; ruffled border formation and clear zone development with cell-matrix attachment were reduced, which suggested that osteoclasts were inactive (15) . Similar morphologic changes are seen when osteoclasts are inhibited by calcitonin (22).
The importance of the parathyroid-inhibitory effect of WR 2721 in producing hypocalcemia is unclear. The nearly identical acute fall in serum calcium levels in the PTX and parathyroidintact rats suggests that the parathyroid-inhibitory effect of WR 2721 plays no role in its acute hypocalcemic effect. There are other interpretations. The nearly identical decline in serum calcium in the two groups could also occur if the parathyroidinhibitory effect contributed to the hypocalcemia in the rats with intact glands. If WR 2721 had no effect on these glands, a compensatory response could, to some degree, blunt the fall in serum calcium. Furthermore, the experimental design probably minimized the contribution of the parathyroid glands, since on a low phosphate diet, the enhanced release of calcium from bone would inhibit PTH secretion and minimize its role in maintaining the serum calcium. Another interpretation of the role of the parathyroid-inhibitory effect is that the consequences of this effect occur later. In these studies we concentrated on the changes in serum calcium in the first 2-3 h after administration of WR 2721. As noted above, the effect of acute hypoparathyroidism may require more time to influence the serum calcium. Further studies are required to distinguish between these various possibilities. Several agents have been described which produce hypocalcemia as a result of inhibiting calcium release from bone. These include calcitonin (16, 17) , mithramycin (18) , protamine (20) , diphosphonates (23, 24) , colchicine (19) , and thiophene-2-carboxylic acid (25) 
